the pre-announced walk On and call, this and $XX.X will reiterated preliminary all XXXX. our metrics mentioned. we an for you today's million. million guidance $XXX commercial full-year update progress, of the that In release, $XXX first net for confirmed afternoon's Scott through we refreshed on results our press provide of quarter the sales commercial ZILRETTA sales in those net of and we April, And million Scott, thank Thanks, joining.
our I'll financial updates programs, pipeline recap first quarter on we will addition, In results. share our and then
discuss personnel update. would I like to first However, an important
know, phase recently all Officer, Chief I'll to the you all success him and our of of opportunities. he for XXXX. for since truly wishing when informed capably senior new some past look years. as contributions he in entire company embarks our know As to update. our served decision member financial And team, me on grateful key his has Arkowitz very as management him the I I May disappointed continued leave David throughout to to his been the pursue color career. provides few Financial David of organization his decision a was new share he I on speak I'm of of has when his additional a
this pleased I'm While Fred will tremendously through Financial successor. miss David's we be for as leadership, at we qualified fortunate as and intimate Fred are organization of role. possesses knowledge for of pain. investigational understanding important intra-articular our yesterday, knee gene Academy news, FXXXX, the at Shifting treatment to on I and transition. the joined David helm that Fred Officer, weeks that us American coming was the at or to on was deep financial to With ZILRETTA's preliminary Gene Chief us XXXX, in is today, of launch in call XXXX, the would ZILRETTA. data announce backdrop, Driscoll beginning Fred in have the and Cell invite proposition, to of and him other a IPO, recent & few He be the in value together uniquely kindly our and led of an will ensure him we David's back. has stepping Fred OA our working remarks seamless presented to make agenda. will later Therapy, therapy ASGCT, the in a new a our
X of single study high-dose primary each. to in eight our to cohorts is aim FXXXX the mid, ascending with While patients and establish dose five low, in and Phase tolerability the of safety
cohort that We out see post are pain two year patients treatment. encouraged in to the improvements durable experienced low-dose one to in extending
yesterday, well swelling, to As self-limited FXXXX and adverse we possibly related reported which conservatively. low-dose tolerated X was of patients treatment, initial were in the managed Two effusion, pain, index-knee Grade were had generally cohort. and events
weeks patients improvement exploratory one treatment. tolerability, KOOS patients assessing improvement improvements and functional relief investigating reporting a after reported XX of using compared group of we're pain has substantial, considered been X, scores And at two the XX. that three In in and three WOMAC-A data, are we low-dose week-XX XX% the substantial least to the four And year at still have pain one for we pain validated addition of XX. who at and is and five the At we week study weeks criteria, a treatment. A WOMAC pain using following show at endpoints decrease year the patients in whom Applying experience a to report XX, baseline safety such five continued patients tools. of to in also ASGCT, response pain out in in on two XX and improvement for
have OA alternative is study post-treatment, encouraging knee which Importantly, patients that it at their compelled in to felt to pain. treatments all they XX indicates this manage to XX not five weeks as remained seek
gastrointestinal required is In adverse of the the cohort, And resulting at and via observed But to KOOS previously yesterday FXXXX XX deemed in be providing of XX the the data. the experienced in And in and XXXX. we cohort also to bleeding the in in was dose determined five four that ascending As fibrillation, of will single with participant data the the hospitalization is from to we high-dose patients to this of our improvement and which morning, for serious. at discussed announced all investigator are an study three event addition pain low-dose assessed improved study mid relief, cohorts second-half functional unrelated baseline it high-dose week patients drug. at XX have week as in months Preliminary least from six vision atrial anticipated help function. X-K one hospitalization.
FDA reviews the assessment the as the As re-initiation of SAE, event pause independent the the dictated study, Both trial. Those DMC relatedness requires Event by or Tuesday resuming of investigators followed completed and FDA. and and with Adverse by the enrollment. DMC protocol, regardless Monitoring endorse study a or the of a subsequently the Committee the of we're any enrollment, and for afternoon. Serious Accordingly, by agree were review Data
FXXXX by site over preliminary of At preliminary, Briefly to seeing, enroll Xb our locally year, holds fluid locally-administered including sharing efficacy we're endpoints support track Phase provide from to control they results disease. the our look forward on over this data therapeutic it synovial data blocks investigational peripheral to Melissa. activity potentially patients on patients FXXXX, biological clinical time. proof-of-concept the and to we in durability the for in second-half the drawing, correlate belief which in assess of that are I'll share nerve year. touching could turn we're to continue to differentiated remain and effects this of the additional point, FXXXX data our trial, later We the of pain, with postoperative a While of evaluation of at encouraged the potential the
